MiNK Therapeutics, Inc. presented promising new data from its Phase 2 study of its innovative iNKT cell therapy, agenT-797, at the AACR IO Annual Meeting, showcasing its potential effectiveness in ...
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focusing on allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune diseases, announced it will present a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback